ribocytokine IL-2 BNT151

{
  "id": "MLC-T-ONC-016533",
  "term": "ribocytokine IL-2 BNT151",
  "field": "Oncology and biomedicine",
  "definition": "A formulation consisting of nucleoside-modified messenger RNA (mRNA) encoding a modified form of the endogenous cytokine interleukin-2 (IL-2), with potential immunostimulating activity. Upon administration, ribocytokine IL-2 BNT151 is taken up by cells and the expressed IL-2 targets and binds to the IL-2 receptor beta subunit (IL2Rb; IL2Rbeta; CD122). The binding of IL-2 to IL2Rb activates IL2Rb-mediated signaling, which activates cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-mediated cytotoxic immune responses against tumor cells causes tumor cell destruction. IL2Rb plays a key role in the proliferation and activation of effector T cells.",
  "synonyms": [
    "modified recombinant human interleukin-2"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ribocytokine-il-2-bnt151/"
}